PE20240684A1 - Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a] pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma - Google Patents

Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a] pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma

Info

Publication number
PE20240684A1
PE20240684A1 PE2023001857A PE2023001857A PE20240684A1 PE 20240684 A1 PE20240684 A1 PE 20240684A1 PE 2023001857 A PE2023001857 A PE 2023001857A PE 2023001857 A PE2023001857 A PE 2023001857A PE 20240684 A1 PE20240684 A1 PE 20240684A1
Authority
PE
Peru
Prior art keywords
formula
optionally substituted
indazole
carboxamide
alkyl
Prior art date
Application number
PE2023001857A
Other languages
English (en)
Spanish (es)
Inventor
Ina Terstiege
Stefan Schiesser
Yafeng Xue
Hui-Fang Chang
Anna Ingrid Kristina Berggren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20240684A1 publication Critical patent/PE20240684A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2023001857A 2020-12-10 2021-12-09 Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a] pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma PE20240684A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063199160P 2020-12-10 2020-12-10
PCT/EP2021/084916 WO2022122876A1 (en) 2020-12-10 2021-12-09 N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma

Publications (1)

Publication Number Publication Date
PE20240684A1 true PE20240684A1 (es) 2024-04-10

Family

ID=79230946

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001857A PE20240684A1 (es) 2020-12-10 2021-12-09 Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a] pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma

Country Status (33)

Country Link
US (3) US11866405B2 (cg-RX-API-DMAC7.html)
EP (1) EP4259632B1 (cg-RX-API-DMAC7.html)
JP (1) JP7749015B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118153A (cg-RX-API-DMAC7.html)
CN (1) CN116583285B (cg-RX-API-DMAC7.html)
AR (1) AR124303A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021395816B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203569A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001662A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007624A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230264A (cg-RX-API-DMAC7.html)
DK (1) DK4259632T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000119A (cg-RX-API-DMAC7.html)
EC (1) ECSP23050553A (cg-RX-API-DMAC7.html)
ES (1) ES2989489T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259632T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241312T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068584T2 (cg-RX-API-DMAC7.html)
IL (1) IL303356B2 (cg-RX-API-DMAC7.html)
LT (1) LT4259632T (cg-RX-API-DMAC7.html)
MA (1) MA62535B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006816A (cg-RX-API-DMAC7.html)
PE (1) PE20240684A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259632T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259632T (cg-RX-API-DMAC7.html)
RS (1) RS66095B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259632T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400417T1 (cg-RX-API-DMAC7.html)
TW (1) TWI902994B (cg-RX-API-DMAC7.html)
UA (1) UA130417C2 (cg-RX-API-DMAC7.html)
UY (1) UY39561A (cg-RX-API-DMAC7.html)
WO (1) WO2022122876A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306848B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152349A1 (en) * 2022-02-14 2023-08-17 Astrazeneca Ab Irak4 inhibitors
US20250326757A1 (en) * 2022-05-26 2025-10-23 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
HUE029617T2 (en) 2010-12-20 2017-03-28 Merck Serono Sa Indazolyl triazole derivatives as IRAK inhibitors
BG111378A (bg) * 2013-01-14 2015-01-30 Николай Цветков Субституирани индазолови производни като in-vitro mao-b инхибитори
RU2665554C2 (ru) * 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA2992406A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CN105503863A (zh) * 2015-12-11 2016-04-20 南京华威医药科技开发有限公司 新型抗肿瘤化合物
EP3394066A2 (en) 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
WO2017207386A1 (de) 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
JP2020524692A (ja) 2017-06-21 2020-08-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Irak4調節因子としてのベンゾフラン
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
KR20220027196A (ko) 2019-06-27 2022-03-07 바이오젠 엠에이 인코포레이티드 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
CN114585609B (zh) 2019-06-27 2024-07-30 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途

Also Published As

Publication number Publication date
DK4259632T3 (da) 2024-10-21
UA130417C2 (uk) 2026-02-11
IL303356B1 (en) 2026-04-01
HRP20241312T1 (hr) 2024-12-20
LT4259632T (lt) 2024-10-10
EP4259632B1 (en) 2024-07-24
PT4259632T (pt) 2024-10-24
CL2023001662A1 (es) 2024-01-12
JP7749015B2 (ja) 2025-10-03
KR20230118153A (ko) 2023-08-10
ES2989489T3 (es) 2024-11-26
AU2021395816B2 (en) 2024-04-04
WO2022122876A1 (en) 2022-06-16
AR124303A1 (es) 2023-03-15
US20220185817A1 (en) 2022-06-16
AU2021395816A9 (en) 2025-03-13
ZA202306848B (en) 2024-04-24
CN116583285A (zh) 2023-08-11
IL303356A (en) 2023-08-01
HUE068584T2 (hu) 2025-01-28
FI4259632T3 (fi) 2024-10-24
TW202237612A (zh) 2022-10-01
EP4259632A1 (en) 2023-10-18
UY39561A (es) 2022-06-30
US11866405B2 (en) 2024-01-09
MX2023006816A (es) 2023-06-21
RS66095B1 (sr) 2024-11-29
ECSP23050553A (es) 2023-08-31
US20240182479A1 (en) 2024-06-06
MA62535B1 (fr) 2024-11-29
CA3203569A1 (en) 2022-06-16
US20260092069A1 (en) 2026-04-02
CR20230264A (es) 2023-07-26
SI4259632T1 (sl) 2024-12-31
IL303356B2 (en) 2026-08-01
CO2023007624A2 (es) 2023-06-30
PL4259632T3 (pl) 2024-12-16
SMT202400417T1 (it) 2024-11-15
CN116583285B (zh) 2026-03-24
US12448385B2 (en) 2025-10-21
TWI902994B (zh) 2025-11-01
AU2021395816A1 (en) 2023-07-13
DOP2023000119A (es) 2023-07-09
JP2023552838A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
ES2927182T3 (es) Agentes inductores de la apoptosis
ES2778898T7 (es) Compuestos inhibidores de la autotaxina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ES2929376T3 (es) Nuevos compuestos
ES2701098T3 (es) Derivados de acilaminopirimidina para el tratamiento de infecciones víricas y otras enfermedades
AR073568A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
ES2632136T3 (es) Derivados de carbamato de hexafluoroisopropilo, su preparación y su aplicación terapéutica
ES2839201T3 (es) Derivados de anillo (hetero)aromático sustituidos en carboxilo y método de preparación y usos de los mismos
ES2687368T3 (es) Inhibidores de proteasa de epoxi cetona dipeptídica y tripeptídica
AR077463A1 (es) Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
RU2010117156A (ru) Гетероциклические соединения в качестве антагонистов crth2 рецептора
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
RU2018121834A (ru) Новое соединение бифенила или его соль
AR099367A1 (es) Inhibidores de la tirosina quinasa de bruton
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR060432A1 (es) Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas
AR070518A1 (es) 4-oxo-naftiridinas y 4-oxo-1,4-dihidroquinolinas, composiciones farmaceuticas y kits que los comprenden y su uso para el tratamiento de infecciones virales.
ES2714100T3 (es) Compuestos de quinolina fusionados como inhibidores de mTor, pi3k
BRPI0807868A2 (pt) Composto ou um sal farmaceuticamente aceitável ou n-óxido do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável ou n-óxido, método para o tratamento de um ser humano ou animal que sofre um câncer, e, processo para preparar um composto ou um sal farmaceuticamente aceitável ou n-óxido do mesmo
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
ES2954148T3 (es) Ciertos inhibidores de proteína cinasa
ES2623304T3 (es) Azaindolinas
TWI572608B (zh) 雙環雜環衍生物、其製備方法及醫療用途
HRP20241312T1 (hr) Derivati n-(imidazo[1,2-b]piridazin-3-il)-1-cikloheksil-2h-indazol-5-karboksamida i n-(pirazolo[1,5-a]pirimidin-3-il)-1-cikloheksil-2h-indazol-5-karboksamida kao inhibitori irak4 za liječenje astme
WO2020077361A1 (en) Compounds and methods of their use